Drug Profile
Icaritin/Pexastimogene devacirepvec - Lees Pharmaceutical Holding/ Beijing Shenogen Pharma
Alternative Names: SNG-162/JX-594; SNG-162/TG-6006Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Lees Pharmaceutical Holdings; Shenogen Pharma
- Developer Lee's Pharmaceutical; Shenogen Pharma
- Class Antineoplastics; Benzopyrans; Flavonoids; Oncolytic viruses; Phenyl ethers; Small molecules
- Mechanism of Action Apoptosis stimulants; Estrogen receptor alpha modulators; Immunostimulants; Vascular disrupting agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Cancer in China